Embecta Corp. — Form 10-Q Summary
Reporting period: Quarter and nine months ended June 30, 2023; filed August 8, 2023. Dollar amounts are in millions except per-share data. Embecta is a standalone medical-device company focused on diabetes care products, including pen needles, syringes and safety devices, with a digital application and an insulin patch pump in development.
Key financial results
| Metric | Three months ended June 30, 2023 | Year-over-year change | Nine months ended June 30, 2023 | Year-over-year change |
|---|---|---|---|---|
| Revenue | $286.1 | (1.7%) | $838.9 | (1.9%) |
| Gross profit / margin | $189.5 / 66.2% | $202.9 / 69.7% | $568.1 / 67.7% | $598.0 / 69.9% |
| Operating income / margin | $51.3 / 17.9% | $97.1 / 33.4% | $195.7 / 23.3% | $312.6 / 36.6% |
| Net income | $15.2 | (75.6%) | $64.4 | (73.3%) |
| Diluted EPS | $0.26 | Prior year: $1.07 | $1.12 | Prior year: $4.14 |
- Cash flow: Nine-month operating cash flow was $38.1, versus $354.2 a year earlier; capital expenditures were $17.3, versus $15.0. Cash declined $13.5 from September 30, 2022, to $317.4.
- Liquidity: Current assets were $787.5 and current liabilities $385.8, including $169.0 due from BD and $68.6 due to BD. Working capital was $401.7. The $500.0 revolving facility was undrawn.
- Debt: Principal debt was $1,638.1, comprising a $938.1 term loan, $500.0 of 5.00% notes and $200.0 of 6.75% notes. Reported long-term debt was $1,595.0; total debt including current obligations was $1,604.5. Weighted-average debt cost was 7.2%. The company reported covenant compliance.
- Other balance-sheet items: Inventories were $170.3, up from $122.8 at September 30, 2022. Equity was negative $809.4.
Material changes and drivers
- Revenue fell modestly, but gross profit and margins declined more materially. For the quarter, management attributed the revenue decrease mainly to unfavorable foreign exchange, lower U.S. price and volume, and reduced contract manufacturing/non-diabetes sales to BD, partly offset by international price and volume gains. For the nine months, foreign exchange was the largest revenue headwind, partly offset by international growth and BD sales.
- Cost of products sold rose 9.5% for the quarter and 5.4% for the nine months. Management cited inflation in raw materials, freight, labor and overhead; nine-month costs also reflected the post-separation cannula supply arrangement with BD.
- Selling and administrative expense increased 4.5% for the quarter and 15.4% for the nine months, primarily from standalone-company headcount and compensation. R&D rose 58.0% and 25.7%, respectively, mainly due to investment in the insulin patch pump program; nine-month expense also included collaboration costs.
- Separation and stand-up costs were $28.0 for the quarter and $65.2 for the nine months, versus $7.7 and $23.5 in the prior-year periods. These included legal, audit, supply-chain, retention, ERP and other standalone-transition costs.
- Interest expense increased to $27.0 for the quarter and $79.4 for the nine months, primarily reflecting higher variable rates and, for the nine-month comparison, debt outstanding for a longer period. The comparison periods include pre-separation results and allocations from BD, which may not represent standalone costs.
- Operating cash flow was pressured by working capital, including a $42.5 inventory build and a $54.8 increase in amounts due from BD, principally for factored receivables not yet collected from BD. The prior-year cash-flow comparison also reflects different receivables and separation-related activity.
Outlook, risks and contingencies
- No quantified full-year guidance was provided in the supplied filing text. Management believes cash, operating cash flow and revolving-credit capacity will be sufficient for foreseeable needs, including working capital, debt service, capital spending and dividends.
- Management expected interest expense on variable-rate debt to rise during the remainder of fiscal 2023 if U.S. benchmark rates continued increasing. A 100-basis-point rate change was estimated to affect annualized term-loan interest expense by $9.4.
- Key risks include pricing pressure and competition, lower-cost providers and commoditization, shifts in diabetes treatment and insulin delivery, inflation and supply-chain disruption, foreign-exchange and interest-rate movements, geopolitical uncertainty, and reliance on BD under separation-related agreements, including cannula supply. The company also noted risks that standalone, ERP and separation costs could exceed expectations.
- Embecta had no material legal proceedings as of the filing. Certain asset and liability transfers in deferred-close jurisdictions remained outstanding; the company estimated $41.0 payable to BD and $7.5 receivable from BD related to those jurisdictions at June 30, 2023.
- A third-party collaboration begun in March 2023 is developing an interoperable automated glycemic controller for the pump program. Embecta expensed an upfront $2.5 payment; future commercialization would involve royalties and additional costs.
Most important facts for investors to verify
- Whether revenue trends, foreign-exchange effects and U.S. pricing/volume stabilize, and whether international growth continues.
- Whether gross margins recover as inflationary, freight and BD supply-agreement costs evolve.
- Progress, spending and potential milestones for the insulin patch pump and controller collaboration.
- Working-capital conversion, inventory levels and collection timing for amounts due from BD, alongside remaining separation and ERP costs.
- Variable-rate debt exposure, covenant headroom, debt-service capacity and the sustainability of dividends given declining operating cash flow.